XARELTO Trousse

Land: Canada

Språk: fransk

Kilde: Health Canada

Aktiv ingrediens:

Rivaroxaban; Rivaroxaban

Tilgjengelig fra:

BAYER INC

ATC-kode:

B01AF01

INN (International Name):

RIVAROXABAN

Dosering :

15MG; 20MG

Legemiddelform:

Trousse

Sammensetning:

Rivaroxaban 15MG; Rivaroxaban 20MG

Administreringsrute:

Orale

Enheter i pakken:

100

Resept typen:

Prescription

Terapeutisk område:

Direct Factor Xa Inhibitors

Produkt oppsummering:

Numéro de groupe d'ingrédients actifs (GIA) :0256950001; AHFS:

Autorisasjon status:

ANNULÉ APRÈS COMMERCIALISATION

Autorisasjon dato:

2018-12-01

Preparatomtale

_XARELTO_
_Product Monograph Page 1 of 97_
PRODUCT MONOGRAPH
PR
XARELTO
®
rivaroxaban tablets
2.5 mg, 10 mg, 15 mg and 20 mg
Anticoagulant
(ATC Classification: B01AF01)
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
Canada
http://www.bayer.ca
Date of Revision:
September 13, 2018
Submission Control No: 211611

2018, Bayer Inc.
® TM see www.bayer.ca/tm-mc
All other trademarks are the property of their respective owners.
_XARELTO_
_Product Monograph Page 2 of 97_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................3
INDICATIONS AND CLINICAL
USE.....................................................................................3
CONTRAINDICATIONS
..........................................................................................................4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE
REACTIONS.........................................................................................................11
DRUG INTERACTIONS
.........................................................................................................26
DOSAGE AND
ADMINISTRATION.....................................................................................30
OVERDOSAGE
.......................................................................................................................36
ACTION AND CLINICAL PHARMACOLOGY
...................................................................38
STORAGE AND
STABILITY.................................................................................................45
DOSAGE FORMS, COMPOSITION AND PACKAGING
1
...................................................45
PART II : SCIENTIFIC INFORMATION
..........................................................................47
PHARMACEUTICAL
INFORMATION..........................